Acorda Therapeutics, Inc.
ACOR
Rang in Aktien
#39156
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Aktienkurs
$0.879
Zuletzt synchronisiert: 2024-05-07
Marktkapitalisierung
$582.38K
Veränderung (1 Tag)
9.88%
Veränderung (1 Jahr)
8,690.00%
Land
US
Handel Acorda Therapeutics, Inc. (ACOR)
Kategorie
Healthcare
EPS für Acorda Therapeutics, Inc. (ACOR)
EPS zum March 2024 TTM: $-262.58
Laut den aktuellen Finanzberichten und dem Aktienkurs von Acorda Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-262.58. Am Ende des Jahres 2022 betrug das EPS $-66.90 eine Steigerung gegenüber dem EPS von 2021, das $-195.75 betrug.
EPS-Verlauf von Acorda Therapeutics, Inc. von 2016 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-262.58 | 28.97% |
| 2023 | $-203.59 | 204.32% |
| 2022 | $-66.90 | -65.82% |
| 2021 | $-195.75 | -20.56% |
| 2020 | $-246.40 | -64.26% |
| 2019 | $-689.42 | -901.84% |
| 2018 | $85.98 | -114.76% |
| 2017 | $-582.69 | 534.81% |
| 2016 | $-91.79 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -100.21% |
IN
|
